CARLSBAD, Calif. / Jan 29, 2024 / Business Wire / Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor conferences:
The live webcasts will be accessible on ATEC’s Investor Relations website.
Long-Range Financial Plan Update
The Company will also present an updated long-range financial plan at the Lotte New York Palace in New York, NY, on March 19, 2024, at 3pm ET. Further detail can be found on ATEC’s Investor Relations website.
Inducement Awards Granted
As an inducement material to accepting employment with the Company, and in accordance with Nasdaq Listing Rule 5635(c)(4), ATEC today announced that the independent Compensation Committee of the Board of Directors has approved aggregate grants to 58 new employees (who are not executive officers) of, collectively, 192,482 restricted stock units (“RSUs”) under the Company’s 2016 Employment Inducement Award Plan. Of those RSUs, 178,780 will vest in equal annual installments on each of the first four anniversaries of the grant date and 13,702 will vest in equal annual installments on each of the first three anniversaries of the grant date provided, in each instance, that the recipient remains continuously employed by ATEC as of such vesting date. In addition, the RSUs will vest fully upon a change of control of ATEC.
About ATEC
ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation MachineTM is focused on developing new approaches that integrate seamlessly with the Company’s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC’s vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.
Last Trade: | US$9.40 |
Daily Change: | 0.28 3.07 |
Daily Volume: | 159,199 |
Market Cap: | US$1.330B |
December 09, 2024 October 30, 2024 September 18, 2024 July 29, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB